UNSPSC 51241123: Amlexanox

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BRL1C2459K, chemically known as 5h-(1)benzopyrano(2,3-b)pyridine-3-carboxylic acid, 2-amino-7-(1-methylethyl)-5-oxo- but generally known as amlexanox, which bears US NIH Compound Identifier 2161. European Medicines Agency schedules Amlexanox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05465MIG.

UNSPSC 51241123 Amlexanox, a Commodity code, describes a topical pharmaceutical agent that state and local governments procure for use in public health clinics, correctional facilities, emergency departments, and dental programs operated or funded by state and county health authorities. Amlexanox is an anti-inflammatory paste used to treat aphthous ulcers (canker sores) and oral lesions; procurement under this code covers the pharmaceutical product itself, typically in single-dose or multi-dose formulations for stocking in formularies or emergency supplies. State and local health departments, county correctional systems, and state university health services have been documented as issuing bodies for pharmaceutical procurement under narrowly specific drug codes such as this one, though activity is sporadic and driven by formulary review cycles, outbreak response, or periodic inventory replenishment rather than continuous demand signals.

The source provided contains no recent state or local contract opportunities, addenda, response dates, or geographic indicators for UNSPSC 51241123. Without current solicitation data, issuing-body concentration and geographic spread cannot be characterized. Firms pursuing pharmaceutical supply contracts with state and local health systems should monitor formulary procurement channels through state health department purchasing offices and multistate cooperative purchasing agreements, and track correctional health-services RFPs at the county and state level where drug-specific line items appear.